文献速递糖尿病

工程化调节性T细胞治疗自身免疫性疾病包括1型糖尿病

Genetic engineering of regulatory T cells for treatment of autoimmune disorders including type 1 diabetes.
PubMed 文献 · Diabetologia · 2024-01-18

综述讨论调节性T细胞(Treg)在多克隆Treg治疗1型糖尿病疗效有限及安全性良好的背景下,基因工程改造Treg以提高抗原特异性、功能和存活率的策略,包括工程化FOXP3表达、表达T细胞受体或嵌合抗原受体及靶向细胞因子通路,并探讨1型糖尿病中Treg工程化的独特机遇与挑战。

要点

  • 多克隆Treg治疗新发1型糖尿病疗效有限但安全性良好。
  • 基因编辑可工程化Treg以提高特异性、功能和存活率。
  • 策略包括工程化FOXP3、表达TCR或CAR及靶向细胞因子通路。

核心结论

  • 基因工程改造Treg是提高1型糖尿病过继细胞治疗疗效的有前景策略,但1型糖尿病具有独特机遇与挑战。

研究设计与样本

  • 综述,讨论Treg在1型糖尿病发病中的作用及Treg工程化在1型糖尿病中的应用。

主要发现

  • 多克隆Treg治疗新发1型糖尿病临床试验疗效有限但安全性良好。
  • 疗效障碍包括缺乏抗原特异性、输注后细胞持久性低及难以生成足够细胞数量。
  • 先进基因编辑技术可工程化Treg以提高特异性与功能。
  • 策略包括工程化FOXP3表达以产生更多抑制细胞来源、表达TCR或CAR以生成抗原特异性Treg、靶向细胞因子通路改善Treg存活。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Suppression of pathogenic immune responses is a major goal in the prevention and treatment of type 1 diabetes. Adoptive cell therapy using regulatory T cells (Tregs), a naturally suppressive immune subset that is often dysfunctional in type 1 diabetes, is a promising approach to achieving localised and specific immune suppression in the pancreas or site of islet transplant. However, clinical trials testing administration of polyclonal Tregs in recent-onset type 1 diabetes have observed limited efficacy despite an excellent safety profile. Several barriers to efficacy have been identified, including lack of antigen specificity, low cell persistence post-administration and difficulty in generating sufficient cell numbers. Fortunately, the emergence of advanced gene editing techniques has opened the door to new strategies to engineer Tregs with improved specificity and function. These strategies include the engineering of FOXP3 expression to produce a larger source of suppressive cells for infusion, expressing T cell receptors or chimeric antigen receptors to generate antigen-specific Tregs and improving Treg survival by targeting cytokine pathways. Although these approaches are being applied in a variety of autoimmune and transplant contexts, type 1 diabetes presents unique opportunities and challenges for the genetic engineering of Tregs for adoptive cell therapy. Here we discuss the role of Tregs in type 1 diabetes pathogenesis and the application of Treg engineering in the context of type 1 diabetes.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Tuomela K, Levings MK. Genetic engineering of regulatory T cells for treatment of autoimmune disorders including type 1 diabetes. Diabetologia. 2024. PMID: 38236408. doi:10.1007/s00125-023-06076-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。